The three major A-share indices collectively fell at the midday break, with CSBIO dropping over 17%

36Kr learned that the three major A-share indices collectively fell during the midday break, with the Shanghai Composite Index down 0.19%, the Shenzhen Component Index down 1.27%, and the ChiNext Index down 1.51%; precious metals, power generation equipment, and pharmaceuticals sectors led the decline, with CSBIO down over 17%, DaJin Heavy Industry down nearly 6%, and Shengda Resources down 5%; the forestry, banking, and insurance sectors saw gains, with Pingtan Development hitting the daily limit, Xiamen Bank up over 6%, and China Life up over 1%

The innovative drug concept fluctuates and declines, CSBIO falls over 15%

In the early trading session, the innovative drug concept fluctuated and fell, with CSBIO dropping over 15%. Yuandong Biotechnology, Rejing Biotechnology, Baiyang Pharmaceutical, Yipinhong, and SanSheng Guojian all fell over 4%

CSBIO's stock price hits a new high

CSBIO rose by 0.08%, closing at 66.34 yuan per share, with the stock price reaching a new high. The total market value exceeded 60.97 billion yuan, and the trading volume reached 489 million yuan

CSBIO released its performance for the first three quarters, with a net loss attributable to shareholders of 44.8174 million yuan

According to the Zhitong Finance APP, CSBIO released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 681 million yuan, a year-on-year decrease of 13.11%. The net loss attributable to shareholders of the listed company was 44.8174 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 47.687 million yuan. The basic loss per share was 0.05 yuan

A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suit